利用定量多模态影像评估治疗反应以实现肉瘤个体化诊疗
本综述汇总了肉瘤患者基于影像的治疗反应监测的临床数据。新的扫描硬件、成像协议、图像重建算法、放射性示踪剂和对比剂使评估与治疗反应相关的肿瘤物理和生物学特性成为可能。影像有望筛选出不能从(新)辅助治疗中获益的肉瘤患者并促进治疗调整,但需针对特定肉瘤亚型获取可行的影像特征集。
要点
- 定量多模态影像可评估与肉瘤治疗反应相关的肿瘤物理和生物学特性。
- 影像有潜力筛选不能从(新)辅助治疗中获益的肉瘤患者并促进治疗调整。
- 肉瘤生物学异质性使针对特定亚型建立可行的反应评估影像特征集成为挑战。
局限性
- 肉瘤存在生物学异质性,针对特定肉瘤亚型获取可行的影像特征集以评估治疗反应仍是挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Over the last decades, technological developments in the field of radiology have resulted in a widespread use of imaging for personalising medicine in oncology, including patients with a sarcoma. New scanner hardware, imaging protocols, image reconstruction algorithms, radiotracers, and contrast media, enabled the assessment of the physical and biological properties of tumours associated with response to treatment. In this context, medical imaging has the potential to select sarcoma patients who do not benefit from (neo-)adjuvant treatment and facilitate treatment adaptation. Due to the biological heterogeneity in sarcomas, the challenge at hand is to acquire a practicable set of imaging features for specific sarcoma subtypes, allowing response assessment. This review provides a comprehensive overview of available clinical data on imaging-based response monitoring in sarcoma patients and future research directions. Eventually, it is expected that imaging-based response monitoring will help to achieve successful modification of (neo)adjuvant treatments and improve clinical care for these patients.
引用
- Kalisvaart GM, Bloem JL, Bovée JVMG, et al. Personalising sarcoma care using quantitative multimodality imaging for response assessment. Clin Radiol. 2021. PMID: 33483087. doi:10.1016/j.crad.2020.12.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。